NANOG and neoplasm: It has been also documented that the overexpression of NANOG as an oncogene along with OCT4 is a prominent characteristic of CSCs and is associated with EMT transition of CSCs and drives tumor progression and poor prognosis in patients with breast and colorectal cancer [73–78].